N

Northwest Research Center | Portland, OR

Research site

(Unclaimed)

Location

6327 SE Milwaukie Avenue, 2nd Floor, Portland, Oregon, United States of America

Site insights

Top conditions

Top treatments

AD109

LY3502970

EDP-938

Orforglipron

LY3454738

Lebrikizumab

S-600918

ADX-629

OPN-375

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 11 total trials

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

This is a US study comparing the efficacy and safety of BDA MDI \[Budesonide/Albuterol Sulfate (BDA) metered dose inhaler (MDI)\] with AS \[Albuterol...

Active, not recruiting

Asthma

Drug: BDA MDI

Drug: AS MDI

Locations recently updated

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling

Chronic Kidney Disease

Overweight

Drug: Orforglipron

Drug: Insulin Glargine

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The stu...

Enrolling

Perennial Allergic Rhinitis (PAR)

Drug: Placebo

Drug: LY3650150

Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting

OSA

Drug: Placebo

Drug: AD109